Neurocrine’s story now hinges on how far its existing medicines can grow and whether its next wave of treatments can reach patients without major setbacks. See what could drive the business forward—and what regulatory, trial, and pricing risks could still derail the outlook.Read more
Neurocrine’s business leans heavily on a small number of flagship medicines, leaving it exposed if insurers push back on coverage, regulators tighten rules, or new rivals take share. At the same time, a growing set of new drug candidates and improving patient access could soften that dependence, making the outlook more balanced than it first appears.Read more
Neurocrine’s INGREZZA could reach far more patients as insurance access improves and more people get diagnosed, while new brain and mental health drugs in development may add extra growth engines. But the company still leans heavily on one main product, and shifting rules, payers, and competition could squeeze sales and profits.Read more
Neurocrine’s lead brain-health medicine keeps gaining traction as insurance coverage widens, and a newer treatment is seeing fast early uptake that could open a second growth engine. At the same time, heavy reliance on a few products and tougher pricing and access negotiations with insurers could make the next chapter bumpier than it looks.Read more
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer’s disease; NBI 921355 for the treatment of epilepsy; NBIP-01435 for the treatment of congenital adrenal hyperplasia; NBIP-2118 for the treatment of obesity and related metabolic diseases; and NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Sanofi S.A.; Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
